Ipilimumab, CTLA-4 inhibitor, the first immune checkpoint inhibitor approved by FDA, was used to treat patients with advanced melanoma and has demonstrated improved survival when given with gp100 melanoma vaccine [142]. This evidence concerns the gene CTLA4 and melanoma.